J.P. Issa
Department of Leukemia and Experimental Therapeutics
The University of Texas M.D. Anderson Cancer Center
Houston
TX 77030
USA
Name/email consistency: high
- Epigenetic changes in the myelodysplastic syndrome. Issa, J.P. Hematol. Oncol. Clin. North Am. (2010)
- Colon cancer: it's CIN or CIMP. Issa, J.P. Clin. Cancer Res. (2008)
- Cancer prevention: epigenetics steps up to the plate. Issa, J.P. Cancer. Prev. Res. (Phila. Pa) (2008)
- DNA methylation as a therapeutic target in cancer. Issa, J.P. Clin. Cancer Res. (2007)
- Azacitidine. Issa, J.P., Kantarjian, H.M., Kirkpatrick, P. Nat. Rev. Drug. Discov (2005)
- Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. Issa, J.P., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., Kantarjian, H.M. J. Clin. Oncol. (2005)
- Azacitidine. Issa, J.P., Kantarjian, H. Nat. Rev. Drug. Discov (2005)
- Decitabine in chronic leukemias. Issa, J.P., Byrd, J.C. Semin. Hematol. (2005)
- Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Issa, J.P. Nature Clinical Practice. Oncology (2005)
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J., Kantarjian, H.M. Blood (2004)
- CpG island methylator phenotype in cancer. Issa, J.P. Nat. Rev. Cancer (2004)
- Age-related epigenetic changes and the immune system. Issa, J.P. Clin. Immunol. (2003)
- Decitabine. Issa, J.P. Curr. Opin. Oncol (2003)
- Epigenetic variation and human disease. Issa, J.P. J. Nutr. (2002)
- Accelerated age-related CpG island methylation in ulcerative colitis. Issa, J.P., Ahuja, N., Toyota, M., Bronner, M.P., Brentnall, T.A. Cancer Res. (2001)